STOCK TITAN

[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Form 4 Overview – Amphastar Pharmaceuticals, Inc. (AMPH)

Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen’s direct ownership stands at 77,531 shares.

No derivative securities were involved and no other transactions were reported.

  • Percentage of holdings sold: roughly 0.6 % of the director’s reported stake.
  • The filing indicates continued direct ownership; no change to indirect holdings was reported.
  • Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.

Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.

Panoramica del Modulo 4 – Amphastar Pharmaceuticals, Inc. (AMPH)

Il direttore Floyd F. Petersen ha comunicato la vendita di 500 azioni delle azioni ordinarie di Amphastar Pharmaceuticals in data 07 luglio 2025 (data di negoziazione 02/07/2025) a un prezzo medio ponderato di 23,4679 $ per azione. L’operazione è stata eseguita nell’ambito di un piano di trading Rule 10b5-1 predefinito, adottato il 26 novembre 2024. Dopo la vendita, la proprietà diretta di Petersen è pari a 77.531 azioni.

Non sono stati coinvolti strumenti derivati né sono state segnalate altre transazioni.

  • Percentuale delle azioni vendute: circa il 0,6% della partecipazione dichiarata dal direttore.
  • La dichiarazione indica il mantenimento della proprietà diretta; non sono stati riportati cambiamenti nella proprietà indiretta.
  • Il piano Rule 10b5-1 suggerisce che la transazione fosse programmata in anticipo, riducendo i rischi di asimmetria informativa.

Considerando la modesta dimensione della vendita rispetto alla proprietà totale e l’uso del piano 10b5-1, l’impatto sul mercato è probabilmente limitato.

Resumen del Formulario 4 – Amphastar Pharmaceuticals, Inc. (AMPH)

El director Floyd F. Petersen reveló la venta de 500 acciones comunes de Amphastar Pharmaceuticals el 07 de julio de 2025 (fecha de operación 02/07/2025) a un precio promedio ponderado de 23,4679 $ por acción. La transacción se realizó bajo un plan de negociación Rule 10b5-1 preestablecido adoptado el 26 de noviembre de 2024. Tras la venta, la propiedad directa de Petersen es de 77,531 acciones.

No se involucraron valores derivados ni se reportaron otras transacciones.

  • Porcentaje de participaciones vendidas: aproximadamente el 0,6% de la participación declarada del director.
  • La presentación indica propiedad directa continua; no se reportaron cambios en la propiedad indirecta.
  • El plan Rule 10b5-1 sugiere que la operación fue programada con anticipación, reduciendo preocupaciones sobre asimetría de información.

Dado el tamaño modesto de la venta en relación con la propiedad total y el uso del plan 10b5-1, es probable que el impacto en el mercado sea limitado.

서식 4 개요 – Amphastar Pharmaceuticals, Inc. (AMPH)

이사 Floyd F. Petersen2025년 7월 7일에 Amphastar Pharmaceuticals 보통주 500주주당 평균 가중 가격 23.4679달러에 매도했다고 공시했습니다(거래일 2025년 7월 2일). 이 거래는 2024년 11월 26일 채택된 사전 계획된 Rule 10b5-1 거래 계획에 따라 실행되었습니다. 매도 후 Petersen의 직접 소유 주식은 77,531주입니다.

파생 증권은 포함되지 않았으며 다른 거래도 보고되지 않았습니다.

  • 매도 지분 비율: 이사가 보고한 지분의 약 0.6%입니다.
  • 신고서에는 직접 소유권이 유지됨을 나타내며 간접 소유권 변경은 보고되지 않았습니다.
  • Rule 10b5-1 계획은 거래가 사전에 예정되었음을 시사하여 정보 비대칭 우려를 줄입니다.

전체 소유권 대비 매도 규모가 작고 10b5-1 계획을 사용했으므로 시장에 미치는 영향은 제한적일 가능성이 높습니다.

Résumé du Formulaire 4 – Amphastar Pharmaceuticals, Inc. (AMPH)

Le directeur Floyd F. Petersen a déclaré la vente de 500 actions ordinaires d’Amphastar Pharmaceuticals le 7 juillet 2025 (date de transaction 02/07/2025) à un prix moyen pondéré de 23,4679 $ par action. La transaction a été réalisée dans le cadre d’un plan de négociation Rule 10b5-1 préétabli adopté le 26 novembre 2024. Après la vente, la détention directe de Petersen s’élève à 77 531 actions.

Aucun instrument dérivé n’a été impliqué et aucune autre transaction n’a été signalée.

  • Pourcentage des actions vendues : environ 0,6 % de la participation déclarée du directeur.
  • Le dépôt indique une détention directe continue ; aucun changement dans les participations indirectes n’a été signalé.
  • Le plan Rule 10b5-1 suggère que la transaction a été planifiée à l’avance, réduisant les risques d’asymétrie d’information.

Compte tenu de la taille modeste de la vente par rapport à la détention totale et de l’utilisation du plan 10b5-1, l’impact sur le marché est probablement limité.

Formular 4 Übersicht – Amphastar Pharmaceuticals, Inc. (AMPH)

Direktor Floyd F. Petersen meldete den Verkauf von 500 Aktien der Amphastar Pharmaceuticals Stammaktien am 07. Juli 2025 (Handelsdatum 02.07.2025) zu einem gewichteten Durchschnittspreis von 23,4679 $ pro Aktie. Die Transaktion wurde im Rahmen eines vorab vereinbarten Rule 10b5-1 Handelsplans durchgeführt, der am 26. November 2024 angenommen wurde. Nach dem Verkauf hält Petersen direkt 77.531 Aktien.

Es waren keine Derivate involviert und es wurden keine weiteren Transaktionen gemeldet.

  • Verkaufter Anteil: etwa 0,6 % des gemeldeten Anteils des Direktors.
  • Die Meldung zeigt weiterhin direkten Besitz; keine Änderungen bei indirekten Beteiligungen wurden gemeldet.
  • Der Rule 10b5-1 Plan deutet darauf hin, dass der Handel im Voraus geplant war, was Bedenken hinsichtlich Informationsasymmetrien verringert.

Angesichts der vergleichsweise geringen Verkaufsgröße und der Nutzung des 10b5-1 Plans ist die Marktauswirkung wahrscheinlich begrenzt.

Positive
  • Use of Rule 10b5-1 plan underscores strong compliance and reduces perception of opportunistic trading.
Negative
  • Insider selling, albeit small, can be perceived as a mildly negative signal by some market participants.

Insights

TL;DR Small 500-share sale (~0.6 % of stake) via 10b5-1 plan; neutral-to-slightly negative signal with minimal impact.

The reported disposition is de minimis for a director holding more than 77 k shares. Use of a Rule 10b5-1 plan mitigates signalling risk because trades were pre-scheduled, but any insider sale can create mild negative sentiment, especially if clustered with other insider activity. No derivatives, no change to beneficial ownership structure, and no other insiders involved, so liquidity impact is negligible. Overall, I classify this event as neutral for valuation, with limited informational value for investors.

TL;DR Pre-planned trade shows compliance discipline; sale size immaterial—impact neutral.

From a governance standpoint, adherence to Rule 10b5-1 demonstrates best practice and reduces litigation risk surrounding insider trading claims. The signature by power of attorney and precise disclosure of weighted-average pricing align with SEC guidance. The transaction does not materially alter the director’s ownership or influence. Accordingly, I view the disclosure as routine housekeeping rather than a directional signal.

Panoramica del Modulo 4 – Amphastar Pharmaceuticals, Inc. (AMPH)

Il direttore Floyd F. Petersen ha comunicato la vendita di 500 azioni delle azioni ordinarie di Amphastar Pharmaceuticals in data 07 luglio 2025 (data di negoziazione 02/07/2025) a un prezzo medio ponderato di 23,4679 $ per azione. L’operazione è stata eseguita nell’ambito di un piano di trading Rule 10b5-1 predefinito, adottato il 26 novembre 2024. Dopo la vendita, la proprietà diretta di Petersen è pari a 77.531 azioni.

Non sono stati coinvolti strumenti derivati né sono state segnalate altre transazioni.

  • Percentuale delle azioni vendute: circa il 0,6% della partecipazione dichiarata dal direttore.
  • La dichiarazione indica il mantenimento della proprietà diretta; non sono stati riportati cambiamenti nella proprietà indiretta.
  • Il piano Rule 10b5-1 suggerisce che la transazione fosse programmata in anticipo, riducendo i rischi di asimmetria informativa.

Considerando la modesta dimensione della vendita rispetto alla proprietà totale e l’uso del piano 10b5-1, l’impatto sul mercato è probabilmente limitato.

Resumen del Formulario 4 – Amphastar Pharmaceuticals, Inc. (AMPH)

El director Floyd F. Petersen reveló la venta de 500 acciones comunes de Amphastar Pharmaceuticals el 07 de julio de 2025 (fecha de operación 02/07/2025) a un precio promedio ponderado de 23,4679 $ por acción. La transacción se realizó bajo un plan de negociación Rule 10b5-1 preestablecido adoptado el 26 de noviembre de 2024. Tras la venta, la propiedad directa de Petersen es de 77,531 acciones.

No se involucraron valores derivados ni se reportaron otras transacciones.

  • Porcentaje de participaciones vendidas: aproximadamente el 0,6% de la participación declarada del director.
  • La presentación indica propiedad directa continua; no se reportaron cambios en la propiedad indirecta.
  • El plan Rule 10b5-1 sugiere que la operación fue programada con anticipación, reduciendo preocupaciones sobre asimetría de información.

Dado el tamaño modesto de la venta en relación con la propiedad total y el uso del plan 10b5-1, es probable que el impacto en el mercado sea limitado.

서식 4 개요 – Amphastar Pharmaceuticals, Inc. (AMPH)

이사 Floyd F. Petersen2025년 7월 7일에 Amphastar Pharmaceuticals 보통주 500주주당 평균 가중 가격 23.4679달러에 매도했다고 공시했습니다(거래일 2025년 7월 2일). 이 거래는 2024년 11월 26일 채택된 사전 계획된 Rule 10b5-1 거래 계획에 따라 실행되었습니다. 매도 후 Petersen의 직접 소유 주식은 77,531주입니다.

파생 증권은 포함되지 않았으며 다른 거래도 보고되지 않았습니다.

  • 매도 지분 비율: 이사가 보고한 지분의 약 0.6%입니다.
  • 신고서에는 직접 소유권이 유지됨을 나타내며 간접 소유권 변경은 보고되지 않았습니다.
  • Rule 10b5-1 계획은 거래가 사전에 예정되었음을 시사하여 정보 비대칭 우려를 줄입니다.

전체 소유권 대비 매도 규모가 작고 10b5-1 계획을 사용했으므로 시장에 미치는 영향은 제한적일 가능성이 높습니다.

Résumé du Formulaire 4 – Amphastar Pharmaceuticals, Inc. (AMPH)

Le directeur Floyd F. Petersen a déclaré la vente de 500 actions ordinaires d’Amphastar Pharmaceuticals le 7 juillet 2025 (date de transaction 02/07/2025) à un prix moyen pondéré de 23,4679 $ par action. La transaction a été réalisée dans le cadre d’un plan de négociation Rule 10b5-1 préétabli adopté le 26 novembre 2024. Après la vente, la détention directe de Petersen s’élève à 77 531 actions.

Aucun instrument dérivé n’a été impliqué et aucune autre transaction n’a été signalée.

  • Pourcentage des actions vendues : environ 0,6 % de la participation déclarée du directeur.
  • Le dépôt indique une détention directe continue ; aucun changement dans les participations indirectes n’a été signalé.
  • Le plan Rule 10b5-1 suggère que la transaction a été planifiée à l’avance, réduisant les risques d’asymétrie d’information.

Compte tenu de la taille modeste de la vente par rapport à la détention totale et de l’utilisation du plan 10b5-1, l’impact sur le marché est probablement limité.

Formular 4 Übersicht – Amphastar Pharmaceuticals, Inc. (AMPH)

Direktor Floyd F. Petersen meldete den Verkauf von 500 Aktien der Amphastar Pharmaceuticals Stammaktien am 07. Juli 2025 (Handelsdatum 02.07.2025) zu einem gewichteten Durchschnittspreis von 23,4679 $ pro Aktie. Die Transaktion wurde im Rahmen eines vorab vereinbarten Rule 10b5-1 Handelsplans durchgeführt, der am 26. November 2024 angenommen wurde. Nach dem Verkauf hält Petersen direkt 77.531 Aktien.

Es waren keine Derivate involviert und es wurden keine weiteren Transaktionen gemeldet.

  • Verkaufter Anteil: etwa 0,6 % des gemeldeten Anteils des Direktors.
  • Die Meldung zeigt weiterhin direkten Besitz; keine Änderungen bei indirekten Beteiligungen wurden gemeldet.
  • Der Rule 10b5-1 Plan deutet darauf hin, dass der Handel im Voraus geplant war, was Bedenken hinsichtlich Informationsasymmetrien verringert.

Angesichts der vergleichsweise geringen Verkaufsgröße und der Nutzung des 10b5-1 Plans ist die Marktauswirkung wahrscheinlich begrenzt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Petersen Floyd F.

(Last) (First) (Middle)
C/O AMPHASTAR PHARMACEUTICALS, INC.
11570 6TH STREET

(Street)
RANCHO CUCAMONGA CA 91730

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Amphastar Pharmaceuticals, Inc. [ AMPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/02/2025 S(1) 500 D $23.4679(2) 77,531 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2024.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.335 to $23.625, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
/s/ Eva Wen, by power of attorney 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Amphastar (AMPH) shares did Director Floyd Petersen sell?

He sold 500 shares on 07/02/2025.

What price did the AMPH shares trade at in the disclosed sale?

The weighted-average sale price was $23.4679, with individual trades between $23.335 and $23.625.

Does Petersen still own AMPH stock after the sale?

Yes, he owns 77,531 shares directly following the transaction.

Was the sale made under a Rule 10b5-1 trading plan?

Yes, the plan was adopted on November 26, 2024.

Is this insider sale considered material to Amphastar’s stock outlook?

Given it represents roughly 0.6 % of his holdings, the market impact is expected to be minimal.
Amphastar Pharma

NASDAQ:AMPH

AMPH Rankings

AMPH Latest News

AMPH Latest SEC Filings

AMPH Stock Data

1.09B
35.98M
22.56%
76.09%
8.66%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
RANCHO CUCAMONGA